Comparative Effectiveness and Safety of Fluticasone-Umeclidinium-Vilanterol and Beclomethasone-Glycopyrronium-Formoterol Single-Inhaler Triple Therapies for COPD: Real-World Observational Study [Response to Letter]
International Journal of Chronic Obstructive Pulmonary Disease · 2026-07 · Volume 21 · 1-3
DOI: 10.2147/copd.s633012 ↗Kurz gefasst
Kommentar in der Zeitschrift International Journal of Chronic Obstructive Pulmonary Disease, 2026-07. Verfasst von Mathew Cherian und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Respiratory Division, McGill University, Montreal, Quebec, Canada. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Themen: COPD
Abstract (Originalsprache)
We thank Prof. Wedzicha and Dr. Kiran for their commentary on our work, in which they question some safety findings reported in our real-world comparative effectiveness and safety study of two single-inhaler triple therapies (SITT), namely fluticasone-umeclidinium-vilanterol (FUV) versus beclomethasone-glycopyrronium-formoterol (BEGF), in patients with COPD from the UK.1,2 First, to increase transparency, the overall hazard ratio (HR) of severe pneumonia (requiring hospitalization) comparing FUV to BEGF of 1.06 (95% CI; 0.99-1.13)was explicitly reported in the Abstract, the Results section of the full text, and in Table 4. 2 It clearly does not reach the threshold of "statistical significance" as the confidence interval includes unity.Note that nowhere in the paper did we use the term "statistical significance" or perform "statistical tests", neither for positive nor negative results, as we believe that readers understand the inference from the confidence interval.Additionally, for all outcomes, the overall result was presented before subgroup findings, ensuring that the reader clearly encounters the overall result prior to the subgroup findings.As such, our conclusions and discussion focused on the clinically relevant subgroups that showed an elevated risk.Second, the authors consider our focus on subgroup analyses as "misleading".However, our subgroup analyses for the effectiveness and safety outcomes were chosen to reflect the very clinical characteristics that GOLD recommends clinicians weigh when initiating pharmacological treatment decisions, 3 including exacerbation history and eosinophil count.Thus, for these key GOLD factors, we reported the HR of severe pneumonia comparing FUV to BEGF of 1.14 (95% CI 1.06-1.24)among those classified as "GOLD Group E" and of 1.10 (95% CI 1.02-1.19)among those with a blood eosinophil count ≤300 cells/μL.Third, Wedzicha and Kiran raise an important point regarding the technical application of the GOLD "Group E" label, defined until 2026 as two or more moderate or one severe exacerbation in the year prior to treatment initiation and proposed for initial treatment.We acknowledge the technical imprecision of applying the GOLD Group E label to patients already receiving maintenance therapy; however, consistent with its widespread use in the GOLD framework, we used it deliberately as a clinically recognizable shorthand for a high exacerbation burden phenotype that is immediately meaningful to the clinicians for whom this research is intended.
Autor:innen und Institutionen
- Department of Medicine, Respiratory Division, McGill University, Montreal, Quebec, Canada.
- Centre for Clinical Epidemiology, Lady Davis Institute-Jewish General Hospital, Montreal, Quebec, Canada.
- Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada.
ORCID-Profile: Samy Suissa
Zitieren
APA
Cherian, M., & Suissa, S. (2026). Comparative Effectiveness and Safety of Fluticasone-Umeclidinium-Vilanterol and Beclomethasone-Glycopyrronium-Formoterol Single-Inhaler Triple Therapies for COPD: Real-World Observational Study [Response to Letter]. International Journal of Chronic Obstructive Pulmonary Disease, Volume 21, 1-3. https://doi.org/10.2147/copd.s633012
Vancouver
Cherian M, Suissa S. Comparative Effectiveness and Safety of Fluticasone-Umeclidinium-Vilanterol and Beclomethasone-Glycopyrronium-Formoterol Single-Inhaler Triple Therapies for COPD: Real-World Observational Study [Response to Letter]. International Journal of Chronic Obstructive Pulmonary Disease. 2026;Volume 21:1-3. doi:10.2147/copd.s633012
BibTeX
@article{Cherian2026,
author = {Cherian, Mathew and Suissa, Samy},
title = {Comparative Effectiveness and Safety of Fluticasone-Umeclidinium-Vilanterol and Beclomethasone-Glycopyrronium-Formoterol Single-Inhaler Triple Therapies for COPD: Real-World Observational Study [Response to Letter]},
journal = {International Journal of Chronic Obstructive Pulmonary Disease},
year = {2026},
volume = {Volume 21},
pages = {1--3},
doi = {10.2147/copd.s633012}
}
EUVIMED